Skip to main content
. 2020 Sep 10;15(8):1533–1544. doi: 10.1007/s11739-020-02485-y

Table 2.

Initial clinical, radiological and laboratory parameters and specific COVID-19 treatment

Characteristics Total (n = 128) Deaths caused by SARS-CoV-2 infection (n = 109) Death with SARS-CoV-2 infection (n = 19) p
Days from illness onset to hospital admission, median (IQR), days 5 (2–7) 5 (2–7) 4 (2–7) 0.944
Signs and symptoms at diagnosis
 Shortness of breath 103 (81%) 86 (79%) 17 (90%) 0.363
 Fever 89 (70%) 80 (73%) 9 (47%) 0.023
 Cough 54 (42%) 50 (46%) 4 (21%) 0.043
 Diarrhoea or vomiting 12 (9%) 12 (11%) 0 (0%) 0.211
 Abdominal pain 7 (6%) 7 (6%) 0 (0%) 0.593
 Anosmia or ageusia 22 (20%) 20 (20%) 2 (11%) 0.404
 Asthenia 17 (13%) 14 (13%) 3 (16%) 0.718
 Arthromyalgia 3 (2%) 3 (3%) 0 (0%) 0.464
 Sore throat 3 (2%) 3 (3%) 0 (0%) 0.464
 Headache 15 (12%) 12 (11%) 3 (16%) 0.550
X-ray/CT scan findings
 Normal 16 (13%) 6 (6%) 10 (54%)  < 0.001
 Unilateral infiltrates 21 (16%) 16 (15%) 5 (26%)
 Bilateral infiltrates 91 (71%) 87 (80%) 4 (21%)
Diagnosis
 RT-PCR positive 123 (96%) 106 (97%) 17 (90%) 0.123
 Ig test positive 4 (3%) 2 (2%) 2 (10%)
 Presumptive diagnosis 1 (1%) 1 (1%) 0 (0%)
Laboratory parameters, median (IQR)
 SaFi 390 (164–432) 390 (289–433) 390 (252–428) 0.928
 PaFi 233 (177–290) 233 (169–295) 233 (195–257) 0.820
 White blood cells, × 109/mL 6700 (4325–10,450) 6500 (4300–10,100) 7900 (5200–12,100) 0.202
 Lymphocytes, × 109/mL 700 (500–1000) 700 (500–900) 1000 (500–1300) 0.074
 Platelets, × 109/mL 173 (122–228) 171 (115–227) 196 (130–230) 0.587
 Haemoglobin, g/dL 130 (118–143) 130 (116–142) 131 (123–144) 0.254
 D-dimer, mg/mL 673 (440–1686) 651 (422–1524) 889 (556–3359) 0.088
 CRP, mg/L 120 (74–223) 121 (75–211) 104 (62–232) 0.754
 Serum ferritin, ng/mL 591 (350–1440) 596 (359–1553) 489 (330–931) 0.321
 Creatinine, mg/dL 1.22 (0.85–1.89) 1.23 (0.85–1.68) 1.19 (0.81–2.12) 0.665
 Sodium 136 (132–140) 135 (131–140) 137 (136–143) 0.071
 ALT, U/l 24 (17.37) 24 (16–35) 20 (18–49) 0.728
 AST, U/l 44 (32–65) 44 (30–66) 48 (33–58) 0.494
 LDH, U/l 429 (330–527) 433 (327–530) 406 (343–508) 0.881
Emergency room (ER) diagnosis
 SARS-CoV-2 was suspected in ER 123 (95%) 104 (95%) 19 (100%) 0.341
 Lung injury was diagnoses in ER 88 (69%) 82 (75%) 6 (32%)  < 0.001
Treatments during study period
 Antibiotic agent 122 (95%) 105 (96%) 17 (90%) 0.391
 Azithromycin 107 (84%) 91 (84%) 16 (84%) 0.356
 Lopinavir and ritonavir 63 (49%) 61 (56%) 2 (11%)  < 0.001
 Hydroxychloroquine 105 (82%) 90 (83%) 15 (80%) 0.747
 Interferon 14 (11%) 14 (13%) 0 (0%) 0.128
 Tocilizumab 4 (3%) 4 (4%) 0 (0%) 1.000
 Corticosteroids 34 (26%) 33 (30%) 1 (5%) 0.238
 Anticoagulants
  LMWH prophylaxis 84 (66%) 71 (65%) 13 (58%) 0.752
  LMWH extended prophylaxis 6 (5%) 6 (6%) 0 (0%)
  LMWH therapy 16 (13%) 13 (13%) 2 (11%)
  Oral anticoagulants 2 (2%) 2 (2%) 0 (0%)
  No anticoagulants 20 (16%) 16 (15%) 4 (21%)
Respiratory support
 High-flow oxygen 2 (1%) 2 (1%) 0 (0%) 0.552
 Non-invasive ventilation 12 (9%) 12 (11%) 0 (0%) 0.211
 Invasive mechanical ventilation 26 (20%) 26 (24%) 0 (0%) 0.013
 ECMO 2 (2%) 2 (2%) 0 (0%) 0.552
 DNR order 20 (16%) 12 (11%) 8 (42%) 0.002

Bold indicate p values that achieve statistical significance (p < 0.05)

Deaths caused by SARS-CoV-2 infection: patients whose death was caused directly by SARS-CoV-2 infection. Death with SARS-CoV-2 infection: Patients where SARS-CoV-2 acted as a precipitating factor to decompensate other chronic or acute pathologies that were the main cause of death.

ALT alanine aminotransferase, AST aspartate aminotransferase, CRP C-reactive protein, DNR Do not resucitate, ECMO extracorporeal membrane oxygenation, LDH lactate dehydrogenase, LMWH low molecular weight heparin, PaFi arterial partial pressure of oxygen/fraction of inspired oxygen, SaFi pulse oximetric saturation/fraction of inspired oxygen